Carboplatin Injection is supplied as a sterile, aqueous solution available in 50 mg/5 mL, 150 mg/15 mL, 450 mg/45 mL or 600 mg/60 mL multi-dose vials containing 10 mg/mL of carboplatin for administration by intravenous infusion.
Carboplatin Injection is indicated for the following:
Initial Treatment of Advanced Ovarian Carcinoma
Carboplatin Injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of Carboplatin Injection and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin vs. cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES).
There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor <2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup.
Secondary Treatment of Advanced Ovarian Carcinoma
Carboplatin Injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.
Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate.
Media Articles Related to Carboplatin
Platinum Chemo: Meaningful Activity in Advanced Breast Ca (CME/CE)
Source: MedPage Today Oncology/Hematology [2015.04.08]
(MedPage Today) -- Cisplatin and carboplatin effective against triple-negative and mutated disease.
Genes Linked to Breast, Ovarian Cancers Act Differently in Each Woman: Study
Source: MedicineNet Cancer Specialty [2015.04.08]
Title: Genes Linked to Breast, Ovarian Cancers Act Differently in Each Woman: Study
Category: Health News
Created: 4/7/2015 12:00:00 AM
Last Editorial Review: 4/8/2015 12:00:00 AM
More Support for PARP Inhibitor in Ovarian Cancer (CME/CE)
Source: MedPage Today Oncology/Hematology [2015.04.01]
(MedPage Today) -- Durable responses seen in patients with heavily pretreated disease.
Progress in Battling Advanced Ovarian Cancer
Source: MedicineNet Ovarian Cancer Specialty [2015.03.30]
Title: Progress in Battling Advanced Ovarian Cancer
Category: Health News
Created: 3/30/2015 12:00:00 AM
Last Editorial Review: 3/30/2015 12:00:00 AM
Novel therapy to treat patients with hereditary breast cancer and ovarian cancer
Source: Breast Cancer News From Medical News Today [2015.03.23]
EU and US have approved accelerated procedure to market promising new treatment with few side effectsEuropean scientists recently discovered a novel therapy to treat a subgroup of patients with...
Published Studies Related to Carboplatin
In vivo intraocular distribution and safety of periocular nanoparticle
carboplatin for treatment of advanced retinoblastoma in humans. 
DESIGN: Prospective, interventional, comparative case series... CONCLUSION: Results may indicate an increased facilitated trans-scleral transport
Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or
without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III
OVATURE multicenter randomized study. 
potential, when combined with weekly AUC2-carboplatin in PROC patients... CONCLUSIONS: Orally delivered PXD showed no evidence of clinical activity, when
Randomized, phase II, placebo-controlled, double-blind study with and without
enzastaurin in combination with paclitaxel and carboplatin as first-line
treatment followed by maintenance treatment in advanced ovarian cancer. 
diagnosed advanced ovarian cancer... CONCLUSION: The PCE combination increased PFS, but it was not significantly
Phase III trial of carboplatin and paclitaxel with or without sorafenib in
metastatic melanoma. 
metastatic melanoma... CONCLUSION: Sorafenib does not improve OS when given in combination with CP for
A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination
with carboplatin/paclitaxel versus placebo in combination with
carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to
platinum-based chemotherapy (AGO-OVAR 2.14). 
xenograft models of human ovarian cancer... CONCLUSIONS: Zibotentan 10mg/day plus carboplatin and paclitaxel did not result
Clinical Trials Related to Carboplatin
Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Patients With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy [Recruiting]
The purpose of this study is to determine if Pemetrexed plus Carboplatin plus Bevacizumab
plus Enzastaurin, followed by maintenance Bevacizumab plus Enzastaurin can extend survival
time without disease progression in the first-line treatment of patients with advanced stage
non-small cell lung cancer.
Alternating Cycles of Carboplatin/Gemcitabine and Carboplatin/Taxol for Advanced Stage NSCLC [Recruiting]
To see the efficacy of using chemotherapies alternatively (carboplatin and gemcitabine alternating with carboplatin and taxol) for pts with stage IIIB (nonresectable and stage IV NSCLC.
Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim Followed by Radiotherapy and Paclitaxel/Carboplatin/ZD1839 in Locally Advanced Unresectable Stage IIIA/B Non-Small Cell Carcinoma of the Lung [Completed]
Patients enrolled on this study will have been diagnosed with non-small cell lung cancer
which cannot be removed by an operation. The standard treatment for this disease is a
combination of chemotherapy and radiation therapy; however, the best way to combine these
treatments is not known. This study will examine if the combination of chemotherapy and
radiotherapy has an increased effect on slowing tumor growth with the addition of a drug
In this study, chemotherapy will be given initially (induction therapy) to try to control the
spread of the cancer. Then radiation and chemotherapy will be given together. Receiving
chemotherapy at the same time as radiation treatments can enhance the effect of the
radiation. In this study, patients will receive a drug called ZD1839. In laboratory tests on
cancer cells, ZD1839 has shown an additive effect when used in combination with radiation.
ZD1839 has also been shown to slow or stop growth in tumors.
The purpose of this study is to determine the side effects and effectiveness of using ZD1839
when used with radiation in this treatment regimen (induction chemotherapy followed by
combination chemotherapy, ZD1839, and radiation therapy).
Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer [Completed]
Taxol and carboplatin are commonly used drugs for the treatment of stage IIIB or IV non small
cell lung carcinoma.
This study compares treatment with Taxol/carboplatin given every 3 weeks to a schedule where
it is given weekly.
The purpose of the study is to determine the most effective and safe schedule for giving
these drugs in non small cell lung carcinoma.
Phase II Trial of Gemcitabine and Carboplatin Followed by Paclitaxel and Carboplatin With Radiation for Stage IIIA/IIIB NSCLC. [Active, not recruiting]
This is a single institution Phase II study for patients with unresectable Stage IIIA and IIIB non-small cell lung cancer. The treatment starts with 2 cycles of gemcitabine and carboplatin followed by concurrent chemotherapy with radiation. The chemoradiation includes using paclitaxel and carboplatin with daily thoracic radiation to a total dose of 74 Gy. Response rate will be determined following the chemotherapy with gemcitabine and carboplatin and evaluated again after the chemoradiation. Treatment toxicities will also be assessed.
Reports of Suspected Carboplatin Side Effects
Febrile Neutropenia (206),
Pyrexia (141), more >>